Astellas Pharma has agreed to acquire privately-held Belgian drug discovery group Odega in a deal wo

Pharma Times ------- Astellas Pharma has agreed to acquire privately-held Belgian drug discovery group Odega in a deal worth up to 800 million Euros. Ogeda is a clinical-stage drug discovery company that discovers and develops small molecule drugs targeting G-protein coupled receptors (GPCRs). The firm’s lead investigational candidate is fezolinetant, a selective NK3 receptor antagonist with positive data from a Phase IIa study for the non-hormonal treatment of menopause-related vasomotor symptoms. To get more in depth information click on the picture below to read the article.